 Economic Times |
Bayer to appeal against India’s patent ruling on Nexavar
Business Line The IPAB also came to the conclusion that even though Bayer had obtained a patent for Nexavar in India in 2008, it could not make available the kidney and liver cancer drug on a large scale at an affordable price within the stipulated time. Rejecting … Patients win over patentsThe Hindu Bayer fails to overturn Nexavar compulsory licence in IndiaPMLiVE India board rules against Bayer in cancer drug patent caseMedCity News Fox Business –China Post all 60 news articles » |
Rehab associated with reduced risk of death in women with CAD – Medical Xpress
Rehab associated with reduced risk of death in women with CADMedical Xpress62.7), and had a higher prevalence of heart failure and diabetes. Interestingly, women who are referred to a program but elect not to attend also seem to have better outcomes th…
Pour Richards to host Organ Donation Awareness event – Community Advocate
|
Pour Richards to host Organ Donation Awareness event
Community Advocate Franklin – A Bone Marrow Drive/Organ Donation Awareness event will be held Sunday, March 10 from 2 to 5 p.m. at Pour Richards, 14 Grove St. Guests are invited to sample beers and wines and enjoy other light refreshments. On hand at the event will be … |
Nagpur as the heart of India – Times of India
Nagpur as the heart of IndiaTimes of IndiaNAGPUR: Nagpur is called the heart of India because of its geographical location, but the term could be used in another sense as well. The city has become a melting pot of cultures as people from all over have …
Black Breast Cancer Survivors Face Higher Heart Failure Risk: Study – Health.com
Black Breast Cancer Survivors Face Higher Heart Failure Risk: StudyHealth.comOf these women, 16 percent later developed heart failure. The rate of heart failure was 21 percent among black women, 16 percent among whites, 13 percent among Hispanics, 12 p…
Electronic discharge tool reduces hospital readmissions in heart failure patients – Science Codex
|
Electronic discharge tool reduces hospital readmissions in heart failure patients
Science Codex SAN FRANCISCO (March 7, 2013) —The use of electronic discharge orders aimed at providing evidence-based decision support and clear instructions to heart failure patients helped increase compliance with quality care measures and lowered hospital … |
Diane R. (Ewers) Smith – Coos Bay World
Diane R. (Ewers) SmithCoos Bay WorldShe was treated with intensive chemo and had a bone marrow and stem cell transplant Oct. 2, 2012 at Mayo Clinic in Phoenix, Ariz. She lived in the transplant house at the Mayo campus until her release Jan. 6, 2013. S…
Family fights insurance company on Twitter after it denied their daughter, 18 … – Daily Mail
 Daily Mail |
Family fights insurance company on Twitter after it denied their daughter, 18 …
Daily Mail While they are overjoyed that Lorelei can now begin the stem cell transplant treatment in Houston, Texas, they’re calling for change against insurance companies making life or death decisions. ‘It’s not OK for me to wonder “Can I fight? Do I have hope? Oklahoma teen cancer patient fights insurance company onlineKOCO Oklahoma City An Oklahoma City family’s fight over insurance heads to TwitterNewsOK.com Woman Takes Her Daughter’s Fight With Cancer To TwitterKOKH FOX25 KOSU all 33 news articles » |
Town backs liver-failure girl – Otago Daily Times
Otago Daily TimesTown backs liver-failure girlOtago Daily TimesOn January 22, the Wards were told the news that Paige was in acute liver failure and had been placed on the organ transplant list. The family received a second blow when they discovered Ni…
Data from First Clinical Trial of GGF2 in Heart Failure Presented at the … – MarketWatch (press release)
|
Data from First Clinical Trial of GGF2 in Heart Failure Presented at the …
MarketWatch (press release) “We have completed the first in human trial with GGF2 in patients with heart failure, and especially want to thank our patients who volunteered for this important study. We are very encouraged by the results,” said Daniel Lenihan, M.D., Professor of … |